Nintedanib, a medication approved for the treatment of idiopathic pulmonary fibrosis, slows the decline in lung function among patients with a broad range of scarring lung diseases. The findings, published in the New England Journal of Medicine, suggest that many more people may benefit from nintedanib than are currently approved for treatment. They also suggest
TUESDAY, Feb. 19, 2019 — Metastasis-free survival is significantly longer among men with nonmetastatic, castration-resistant prostate cancer treated with darolutamide versus placebo, according to a phase 3 study published online Feb. 14 in the New England Journal of Medicine to coincide with the American Society of Clinical Oncology annual Genitourinary Cancers Symposium, held from Feb.
Maintaining equal growth rates in opposing limbs is crucial for animals to achieve a symmetrical adult form; what happens if something goes wrong with one limb during development? According to a study publishing June 26 in the open access journal PLOS Biology by Alberto Roselló-Díez, Alexandra Joyner, and colleagues of the Sloan Kettering Institute in
The combination of taselisib and fulvestrant has shown to slow the growth of cancer in post-menopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2) negative, PIK3CA-mutant, inoperable, locally advanced or metastatic breast cancer. Researchers from Memorial Sloan Kettering Cancer Center (MSK) presented this data, from the SANDPIPER trial, in a press conference
The Defocus Incorporated Multiple Segments (DIMS) Spectacle Lens developed by the Hong Kong Polytechnic University (PolyU) slowed down myopia progress by 60 percent in participating children; myopic progression halted completely in 21.5 percent of subjects. This lens will be launched in summer 2018, offering a non-contact, spectacle lens solution to myopic children. The lens was
In collaboration with a number of American colleagues, researchers from Uppsala University have found an Achilles’ heel for the most common form of malignant child brain tumours. By combining two kinds of medicines, it is possible to simultaneously attack the cancer cell’s division and its reinforcement system, which is necessary in order for treatment to